Senior Associates Scientist - Genotyping
Regeneron Pharmaceuticals
Summary
We are looking for a motivated Scientist to join the Genotyping Group at VelociGene. As a Scientist, your primary responsibility will be genotyping complex genetically modified models utilizing state-of-the-art technology platforms to support our R&D and Technology Development efforts for drug discovery.
Job description
Discover your role:
- Processing biopsy samples for downstream extraction and genotyping analysis.
- Using high-throughput automation for DNA isolation from embryonic stem cells and rodent biopsies.
- Strategically selecting and implementing genotyping methodologies to establish workflow priorities.
- Operating applications that create worklists for qPCR assay retrieval and bulk master mix preparation on Hamilton Liquid Handler.
- Orchestrating multiple processes to begin the aliquoting of qPCR master mixes.
- Setting up complex qPCR reactions across multiple Beckman i7 Liquid Handlers.
- Initiating qPCR using the state-of-the-art customized cycling platform.
- Collecting, organizing, and analyzing raw data files with custom data analysis tools.
- Reporting genotyping results through LIMS and initiating discussions with collaborators if needed.
- Performing conventional PCR or Southern Blotting Techniques as a genotyping alternative to qPCR.
- Maintaining comprehensive sample management systems and assay inventory effectively.
This role requires:
- Can multi-task assignments and operate effectively in the face of ambiguity and change.
- Bachelor’s or Master’s degree in biology, molecular biology, or related biological sciences with a minimum of 3 years of experience.
- Are highly motivated with a genuine curiosity for rodent genetics.
- Maintain scientific rigor and familiarity with best practices.
- Leverage automation to drive scientific advancement.
- Drive innovation by developing novel approaches and optimizing existing platforms to increase efficiency and data quality.
- Preferred: Prior experience in a screening laboratory and/or automation laboratory.
- Preferred: Knowledge of coding languages (R, Python, Shiny web framework).
Requirements
- Bachelor’s or Master’s degree in biology, molecular biology, or related biological sciences
- Minimum of 3 years of experience
- Proficiency in molecular biology techniques
- Experience with laboratory automation
- Ability to multi-task and operate effectively in ambiguity
- Genuine curiosity for rodent genetics
- Maintain scientific rigor and best practices
- Leverage automation to drive scientific advancement
- Drive innovation by developing novel approaches
- Preferred: Prior experience in a screening laboratory and/or automation laboratory
- Preferred: Knowledge of coding languages (R, Python, Shiny web framework)
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.